Cancer is currently ineffectively treated using therapeutic drugs, and is also able to resist
drug action, resulting in increased side effects following drug treatment. A novel therapeutic …

In the history of therapeutics, covalent drugs occupy a very distinct category. While
representing a significant fraction of the drugs on the market, very few have been …

Peptide therapy has started since 1920s with the advent of insulin application, and now it
has emerged as a new approach in treatment of diseases including cancer. Using anti …

Over 2 decades ago, the proteasome was considered a risky or even untenable therapeutic
target. Today, proteasome inhibitors are a mainstay in the treatment of multiple myeloma …

Proteasomes are multienzyme complexes that maintain protein homeostasis (proteostasis)
and important cellular functions through the degradation of misfolded, redundant, and …

Metal complexes gained more attention in the medical field, particularly cancer treatment,
due to their enhanced potential and redox ability. These complexes exhibited more …

The ubiquitin-proteasome system (UPS) is the major non-lysosomal proteolytic system for
the degradation of abnormal or damaged proteins no longer required. The proteasome is …

Antimicrobial peptides (AMPs) have been known as host-defense peptides. These cationic
and amphipathic peptides are relatively short (∼ 5–50 L-amino acids) with molecular weight …

Proteasomes are broadly expressed key components of the ubiquitin-dependent protein
degradation pathway containing catalytically active subunits (β1, β2, and β5). LMP7 (β5i) is …

The development of natural product-derived drugs has some unique problems associated
with the process, which can be best described as the “problem of supply”. In this short …